Search Results

You are looking at 1 - 10 of 24 items for :

  • "radioactive iodine refractory" x
Clear All
Pepijn van Houten Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Pepijn van Houten in
Google Scholar
PubMed
Close
,
James Nagarajah Roentgeninstitut Duesseldorf, Duesseldorf, Germany
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by James Nagarajah in
Google Scholar
PubMed
Close
,
Janneke E W Walraven Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Janneke E W Walraven in
Google Scholar
PubMed
Close
,
Martin Jaeger Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Martin Jaeger in
Google Scholar
PubMed
Close
,
Adriana C H van Engen-van Grunsven Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Adriana C H van Engen-van Grunsven in
Google Scholar
PubMed
Close
,
Johannes W Smit Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands

Search for other papers by Johannes W Smit in
Google Scholar
PubMed
Close
, and
Romana T Netea-Maier Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, the Netherlands
Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed
Close

-Serrano F Cochand-Priollet B Leroy K Garinet S Pasmant E Zerbit J , et al . Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer . Thyroid 2022 32 594 – 598 . ( https://doi.org/10

Open access
Alice Nervo Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Alice Nervo in
Google Scholar
PubMed
Close
,
Alberto Ragni Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Alberto Ragni in
Google Scholar
PubMed
Close
,
Alessandro Piovesan Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Alessandro Piovesan in
Google Scholar
PubMed
Close
,
Valentina Marica Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Valentina Marica in
Google Scholar
PubMed
Close
,
Enrica Migliore Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Enrica Migliore in
Google Scholar
PubMed
Close
,
Marco Gallo Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Marco Gallo in
Google Scholar
PubMed
Close
, and
Emanuela Arvat Oncological Endocrinology Unit, Department of Medical Sciences, University of Turin, Città della Salute e della Scienza Hospital, Turin, Italy

Search for other papers by Emanuela Arvat in
Google Scholar
PubMed
Close

Introduction Treatment with lenvatinib (LEN), a multitarget tyrosine kinase inhibitor (TKI), has shown great efficacy in patients with advanced radioactive iodine-refractory (RAI-R) thyroid cancer (TC), both in clinical trials and in a real

Free access
Andrew G Gianoukakis The Lundquist Institute at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Torrance, California, USA

Search for other papers by Andrew G Gianoukakis in
Google Scholar
PubMed
Close
,
Jennifer H Choe Department of Medicine, Duke University Medical Center/Duke Cancer Institute, Durham, North Carolina, USA

Search for other papers by Jennifer H Choe in
Google Scholar
PubMed
Close
,
Daniel W Bowles Division of Medical Oncology, University of Colorado, Aurora, Colorado, USA

Search for other papers by Daniel W Bowles in
Google Scholar
PubMed
Close
,
Marcia S Brose Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Search for other papers by Marcia S Brose in
Google Scholar
PubMed
Close
,
Lori J Wirth Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

Search for other papers by Lori J Wirth in
Google Scholar
PubMed
Close
,
Taofeek Owonikoko Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

Search for other papers by Taofeek Owonikoko in
Google Scholar
PubMed
Close
,
Svetlana Babajanyan Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA

Search for other papers by Svetlana Babajanyan in
Google Scholar
PubMed
Close
, and
Francis P Worden Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA

Search for other papers by Francis P Worden in
Google Scholar
PubMed
Close

. Available at: https://seer.cancer.gov/csr/1975_2017/ 2 Worden F . Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer . Therapeutic Advances in Medical Oncology 2014 6 267 – 279 . ( https://doi.org/10

Open access
Carla Colombo Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed
Close
,
Daniele Ceruti Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Close
,
Simone De Leo Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed
Close
,
Grzegorz Bilo Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed
Close
,
Matteo Trevisan Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Close
,
Noemi Giancola Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Noemi Giancola in
Google Scholar
PubMed
Close
,
Claudia Moneta Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Close
,
Gianfranco Parati Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Search for other papers by Gianfranco Parati in
Google Scholar
PubMed
Close
,
Luca Persani Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Luca Persani in
Google Scholar
PubMed
Close
, and
Laura Fugazzola Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Close

-up of advanced radioiodine-refractory thyroid cancer . European Thyroid Journal 2019 8 227 – 245 . ( https://doi.org/10.1159/000502229 ) 2 Dadu R & Cabanillas ME . Optimizing therapy for radioactive iodine-refractory differentiated thyroid

Open access
Xian Qiu Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Search for other papers by Xian Qiu in
Google Scholar
PubMed
Close
,
Lin Cheng Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Search for other papers by Lin Cheng in
Google Scholar
PubMed
Close
,
Ri Sa Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, China

Search for other papers by Ri Sa in
Google Scholar
PubMed
Close
,
Hao Fu Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China

Search for other papers by Hao Fu in
Google Scholar
PubMed
Close
,
Yuchen Jin Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Close
, and
Libo Chen Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Search for other papers by Libo Chen in
Google Scholar
PubMed
Close

.1634/theoncologist.2015-0107 ) 4 Brose MS Nutting CM Jarzab B Elisei R Siena S Bastholt L de la Fouchardiere C Pacini F Paschke R Shong YK Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer

Open access
Abdul Rehman Syed University of Calgary, Calgary, Alberta, Canada

Search for other papers by Abdul Rehman Syed in
Google Scholar
PubMed
Close
,
Aakash Gorana Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada

Search for other papers by Aakash Gorana in
Google Scholar
PubMed
Close
,
Erik Nohr Alberta Precision Laboratories, Molecular Pathology Program, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Erik Nohr in
Google Scholar
PubMed
Close
,
Xiaoli-Kat Yuan Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by Xiaoli-Kat Yuan in
Google Scholar
PubMed
Close
,
Parthiv Amin MASc Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada

Search for other papers by Parthiv Amin MASc in
Google Scholar
PubMed
Close
,
Sana Ghaznavi Arnie Charbonneau Cancer Institute, Department of Medicine, Section of Endocrinology, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Sana Ghaznavi in
Google Scholar
PubMed
Close
,
Debbie Lamb Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada

Search for other papers by Debbie Lamb in
Google Scholar
PubMed
Close
,
John McIntyre Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Search for other papers by John McIntyre in
Google Scholar
PubMed
Close
,
Markus Eszlinger Department of Oncology, Cumming School of Medicine, and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Markus Eszlinger in
Google Scholar
PubMed
Close
, and
Ralf Paschke Departments of Medicine, Section of Endocrinology, Oncology, Pathology and Laboratory Medicine, Biochemistry and Molecular Biology and Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Ralf Paschke in
Google Scholar
PubMed
Close

Pasmant E Zerbit J , et al. Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer . Thyroid 2022 32 594 – 598 . ( https://doi.org/10.1089/thy.2021.0524 ) 12 Goring S & Mahood Q

Open access
João Roque Endocrinology, Diabetes and Metabolism Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal

Search for other papers by João Roque in
Google Scholar
PubMed
Close
,
Tiago Nunes Silva Endocrinology, Diabetes and Metabolism Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
NOVA Medical School | Faculdade de Ciências Médicas of Universidade NOVA de Lisboa, Lisbon, Portugal
Unidade Investigação Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Tiago Nunes Silva in
Google Scholar
PubMed
Close
,
Catarina Regala Endocrinology, Diabetes and Metabolism Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Catarina Regala in
Google Scholar
PubMed
Close
,
Ricardo Rodrigues Unidade Investigação Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
Close
, and
Valeriano Leite Endocrinology, Diabetes and Metabolism Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
NOVA Medical School | Faculdade de Ciências Médicas of Universidade NOVA de Lisboa, Lisbon, Portugal
Unidade Investigação Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Close

2021 22 1126 – 1138 . ( https://doi.org/10.1016/S1470-2045(2100332-6 ) 9 Brose MS Nutting CM Jarzab B Elisei R Siena S Bastholt L de la Fouchardiere C Pacini F Paschke R Shong YK , Sorafenib in radioactive iodine-refractory

Open access
Kirsten E. Stewart Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom

Search for other papers by Kirsten E. Stewart in
Google Scholar
PubMed
Close
,
Mark W.J. Strachan Metabolic Unit, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Mark W.J. Strachan in
Google Scholar
PubMed
Close
,
Devraj Srinivasan Department of Oncology, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Devraj Srinivasan in
Google Scholar
PubMed
Close
,
Morna MacNeill Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Search for other papers by Morna MacNeill in
Google Scholar
PubMed
Close
,
Lucy Wall Department of Oncology, Western General Hospital, Edinburgh, United Kingdom

Search for other papers by Lucy Wall in
Google Scholar
PubMed
Close
, and
Iain J. Nixon Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom

Search for other papers by Iain J. Nixon in
Google Scholar
PubMed
Close

deemed unsuitable for surgery, limited alternative options were available. Sorafenib and lenvatinib both showed a prolonged progression-free survival advantage in patients with radioactive iodine-refractory differentiated thyroid cancer (DTC

Free access
Francisco Sousa Santos Endocrinology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Francisco Sousa Santos in
Google Scholar
PubMed
Close
,
Rita Joana Santos Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Close
, and
Valeriano Leite Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Faculty of Medical Sciences of Lisbon, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Close

. 10.1530/EJE-16-0202 27666535 0804-4643 7 Brose MS , Nutting CM , Jarzab B , Elisei R , Siena S , Bastholt L , et al. ; DECISION investigators . Sorafenib in radioactive iodine-refractory, locally advanced or metastatic

Free access
Daniela Dias Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Daniela Dias in
Google Scholar
PubMed
Close
,
Inês Damásio Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Inês Damásio in
Google Scholar
PubMed
Close
,
Pedro Marques Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte (CHULN), Lisbon, Portugal

Search for other papers by Pedro Marques in
Google Scholar
PubMed
Close
,
Helder Simões Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Helder Simões in
Google Scholar
PubMed
Close
,
Ricardo Rodrigues Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
Close
,
Branca Maria Cavaco Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Close
, and
Valeriano Leite Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School: Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Close

Established facts Patients with radioactive iodine-refractory differentiated thyroid cancer account for two-thirds of patients with distant metastasis. In the past years, novel targeted therapies directed to specific genes have been

Open access